Navigating Multimodality Therapy in Non-Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches
{{output}}
Neoadjuvant and perioperative immunotherapy have redefined the treatment landscape for select patients with early-stage and locally-advanced resectable non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis combined with... ...
